Welcome to Wellsmont Group website.
The Wellsmont Group is focused on consulting services for Precision Medicine and Precision Oncology.
The company was founded on the principle that complex topics in human health can be simplified into readily understandable concepts. These concepts can be reviewed against unmet clinical need, current standards of care, and rigorous review of clinical evidence to advance precision medicine.
Key steps in this evaluation process within Precision Medicine:
(1) Understand how disease testing and characterization methods align with improved disease understanding, leading to individualized treatment options that impact patient care and improve outcomes.
(2) Evaluate new testing or treatment options against the context of current standard of care and medicine society guideline recommendations.
(3) Rigorous review of available clinical evidence.
(4) Key stakeholder feedback and engagement with early adopter evaluations.
(5) Creation of a publication and communication strategy that positions new technologies for successful impact to patient care and improved outcome.
The Wellsmont Group’s unique approach to consulting employs various steps in the evaluation process of precision medicine solutions to help define a successful commercialization plan.
Founder and Executive Director
The Wellsmont Group was founded by Douglas P. Malinowski, Ph.D., who is an experienced healthcare executive with 41 years of experience in the diagnostics industry. His executive leadership has focused on developing innovative products to address unmet needs in human healthcare and create value for the healthcare system and stakeholders.
Dr. Malinowski’s professional career included the development and commercialization of diagnostic products in infectious disease testing, molecular diagnostics, oncology-based screening and detection, oncology-based diagnostic and prognostic assays, molecular pathology, computational pathology, cytology, and histopathology.
Dr. Malinowski is experienced in all phases of strategy development, innovation management, R&D portfolio management, technology development, biomarker research, translational research, assay prototype development, product development and commercialization. Commercialization and post launch support of products included regulatory approval support, clinical evidence surveillance and synthesis, global scientific affairs management, global key opinion leader engagement.